Semaglutide
STEP UP
Novo Nordisk · Phase 3 · Completed · Enrollment 1407
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Semaglutide 7.2 mg | Obesity or overweight | 7.2 mg | 72 | ITT | -18.8% at week 72 |
| Semaglutide 2.4 mg | Obesity or overweight | 2.4 mg | 72 | ITT | -15.5% at week 72 |
| Placebo | Obesity or overweight | n/r | 72 | ITT | -3.9% at week 72 |